Skip to main content
. 2022 Feb 16;6(4):1264–1270. doi: 10.1182/bloodadvances.2020004169

Table 1.

Characteristics of cohort, by survival status

Characteristics Survivors (n = 184) Died during follow-up (n = 29) Died during first iTTP episode (n = 9) Total cohort (N = 222) P *
Female sex 72.8% 55.2% 66.7% 70.3% .053
Race .070
 White 44.6% 65.5% 33.3% 46.8%
 African American 53.8% 31.0% 44.4% 50.5%
 Other/unknown 1.6% 3.4% 22.2% 2.7%
Age (y), median (IQR) 41 (28, 55) 42 (31,50) 44 (35, 77) 42 (29, 55) .451
Total no. of iTTP episodes, median (IQR) 1 (1,3) 3 (1,5) 1 (1,1) 1 (1,3) <.001
Comorbidities
 Hypertension 48.9% 62.1% 66.7% 51.4% .188
 Diabetes 23.4% 31.0% 33.3.% 24.8% .372
 Obesity (BMI > 30) 37.5% 27.6% 33.3% 35.0% .302
 Hyperlipidemia 23.9% 24.1% 11.1% 23.4% .979
 Atrial fibrillation 7.1% 6.9% 11.1% 7.2% .974
 Systemic lupus erythematosus 9.8% 6.9% 0.0% 9.0% .620
 CKD 19.0% 48.3% 11.1% 22.5% .001
Average remission ADAMT13 activity, median (IQR) 63.2 (42.9, 82.1) 39.0 (23.9, 64.0) n/a 61.2 (37.9, 78.6) .010
Follow-up time (y), median (IQR) 4.8 (0.7, 11.8) 5.3 (0.8,8.0) n/a 4.5 (0.4, 11.5) .975

BMI, body mass index.

*

P values are for differences between patients who died after surviving their first iTTP episode (n = 29) and those who were alive at the end of follow-up (n = 184).

Median (IQR) follow-up time for patients who died during the first iTTP episode was 0.013 (0.002, 0.021) years.